(2Z,3E)-5'-Fluoro-3-((2-(1-methylpiperidin-2-yl)ethoxy)imino)-[2,3'-biindolinylidene]-2'-one

ID: ALA5181676

PubChem CID: 168272876

Max Phase: Preclinical

Molecular Formula: C24H25FN4O2

Molecular Weight: 420.49

Names and Identifiers

Canonical SMILES:  CN1CCCCC1CCO/N=C1C(=C2/C(=O)Nc3ccc(F)cc32)/Nc2ccccc2/1

Standard InChI:  InChI=1S/C24H25FN4O2/c1-29-12-5-4-6-16(29)11-13-31-28-22-17-7-2-3-8-19(17)26-23(22)21-18-14-15(25)9-10-20(18)27-24(21)30/h2-3,7-10,14,16,26H,4-6,11-13H2,1H3,(H,27,30)/b23-21-,28-22+

Standard InChI Key:  JPXSXPOIEBEDOM-YRZTTZRYSA-N

Molfile:  

 
     RDKit          2D

 31 35  0  0  0  0  0  0  0  0999 V2000
   -1.9525   -1.3868    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6671   -1.7991    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6671   -2.6276    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3808    0.7303    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    2.6671   -1.0515    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4122   -0.2494    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0231   -0.6858    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5944   -0.0667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4145   -2.8066    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0935   -1.6730    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2720   -1.4876    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8594   -2.2022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4578   -2.8698    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0342   -2.2022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4364   -1.5485    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2406   -1.7987    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2406   -2.6239    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9508   -3.0356    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2009   -3.6037    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2229   -0.7514    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.4177    1.6397    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1657    2.2232    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0478    3.0202    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5356    3.6037    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5462    2.5931    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3326    3.3901    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9627    2.0096    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1763    1.2125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5928    0.6290    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8064   -0.1679    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.1744   -2.4744    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  5  6  2  0
  8  4  1  0
  8  7  2  0
  6  8  1  0
 10  5  1  0
 11  7  1  0
 11 10  2  0
 12  9  1  0
 11 12  1  0
 12 14  2  0
 13 14  1  0
 15 14  1  0
 16 15  1  0
 16  1  1  0
 17 13  1  0
 17 16  2  0
  3 18  2  0
 18 17  1  0
  9 19  2  0
 15 20  2  0
 22 21  1  0
 22 23  1  0
 23 24  1  0
 24 26  1  0
 26 25  1  0
 25 27  1  0
 27 22  1  0
 28 27  1  0
 29 28  1  0
 29 30  1  0
 20 30  1  0
  9 31  1  0
 10 31  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5181676

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 420.49

Molecular Weight (Monoisotopic): 420.1962

AlogP: 4.21

#Rotatable Bonds: 4

Polar Surface Area: 65.96

Molecular Species: BASE

HBA: 5

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 10.69

CX Basic pKa: 9.57

CX LogP: 3.07

CX LogD: 1.11

Aromatic Rings: 2

Heavy Atoms: 31

QED Weighted: 0.44

Np Likeness Score: -0.38

References

1. Lee SB, Chang TY, Lee NZ, Yu ZY, Liu CY, Lee HY..  (2022)  Design, synthesis and biological evaluation of bisindole derivatives as anticancer agents against Tousled-like kinases.,  227  [PMID:34662748] [10.1016/j.ejmech.2021.113904]

2. Miknis, Greg F; Stevens, Sarah J; Smith, Luke E; Ostrov, David A and Churchill, Mair E A.  2015-02-15  Development of novel Asf1-H3/H4 inhibitors.  [PMID:25582598]

Source

Source(1):

• Scientific Literature